VIDEO: Study results from China on advanced RCC treatment could have global impact
Click Here to Manage Email Alerts
MADRID — In this video, Toni Choueiri, MD, talked about “a very important study” from China in advanced renal cell carcinoma presented at ESMO Congress.
Results from the study showed that treatment with toripalimab (Junshi Biosciences), a monoclonal anti-PD-1 antibody, plus axitinib (Inlyta, Pfizer) yielded significantly longer PFS and higher overall response rate than treatment with sunitinib (Sutent, Pfizer) in patients with previously untreated advanced RCC.
“We did not have any PD-1 drugs approved in China, and China contributes to a large number worldwide of kidney cancer deaths,” Choueiri, director of the Lank Center for Genitourinary Cancer at Dana-Farber Cancer Institute, said. “I think this is very important to expand it globally.... ESMO is a global society and I love to see that abstract here.”
Reference:
- Sheng X, et al. Abstract 18820. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Collapse
Read more about
Click Here to Manage Email Alerts